What Can You Expect in 2026?
Standing as the field’s definitive event uniting stakeholders across biotech, academia, investment and more, the 10th Microbiome Movement Summit Europe remains the forum driving the translation of microbial research into impactful therapeutics for patients across a variety of indications.
As clinical readouts continue to roll in, next year’s meeting looks to dive deeper than the standard readouts, to understand the mechanistic process of these therapeutics, potential implications in broader indications or combination therapies, and how these scientific fundamentals can ultimately support translatability to clinical efficacy and patient benefit.

Unmissable Event Highlights
Explore Clinical Trial Design Innovations Across Modalities
You will gain actionable insights into optimising clinical trial design for LBPs, FMTs, and novel consortia, from patient selection and endpoint refinement to combination strategies. Unpack case studies from Concerto Biosciences, AOBiome, and Microviable Therapeutics to highlight how mechanistic understanding can reshape trial success.
Unlock Emerging Therapeutic Frontiers in GI & Beyond
Discover how the microbiome is transforming treatments across dermatology, metabolic disorders, respiratory disease, and the gut–brain axis. From dual-strain LBPs for atopic dermatitis to microbial co-therapies to treat neuroinflammation, expect to delve into cross-indication innovation.
Navigate the Evolving Investment & Commercial Landscape
Hear directly from leading investors including Seventure Partners, CSB, and Zcube on how to build microbiome ventures that attract capital. Gain insights into structuring deals, demonstrating scalability, and positioning platforms for strategic investment. Early-stage companies will also have the opportunity to pitch live, receiving feedback from investors and industry experts to foster visibility and potential partnerships.
Delve into Mechanisms of Action with Cutting-Edge Analytical Tools
Explore how AI, spatial biology, and multi-omic integration are advancing target discovery, strain selection, and clinical translation. KU Leuven and PharmaBiome will demonstrate how to overcome data integrity challenges and scale innovation from bench to bedside.
Attending Companies Include








